New Products & Services

Waltham, MA-Praecis Pharmaceuticals has received FDA approval to market abarelix (Plenaxis) for men with advanced prostate cancer.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria